The ECM protein EFEMP1 (fibulin-3) is associated with all types of solid tumor through its cell context-dependent dual function. A variant of fibulin-3 was engineered by truncation and mutation to alleviate its oncogenic function, specifically the proinvasive role in glioblastoma multiforme (GBM) cells at stem-like state. ZR30 is an in vitro synthesized 39-kDa protein of human fibulin-3 variant. It has a therapeutic effect in intracranial xenograft models of human GBM, through suppression of epidermal growth factor receptor/AKT and NOTCH1/AKT signaling in GBM cells and extracellular MMP2 activation. Glioblastoma multiforme is highly vascular, with leaky blood vessels formed by tumor cells expressing endothelial cell markers, including CD31.
| INTRODUC TI ON
Malignant gliomas are the most dangerous of primary brain tumors.
Glioblastoma multiforme (GBM) is the most common, most aggressive, and highest grade of malignant glioma, with an average median survival of only 12-14 months. 1 Radical surgical resection followed by adjuvant radiotherapy/chemotherapy is standard treatment for malignant gliomas, however, tumor recurrence occurs in nearly all instances. Human fibulin-3 variant (h-fibulin-3-v), a novel cancer therapeutic agent, has been developed in our laboratory after recognizing that its parental protein EFEMP1 has a role in cancer evolution with a cell context-dependent dual function. [2] [3] [4] Human fibulin-3 variant functions in the extracellular compartment through multifaceted tumor suppression mechanisms. As such, it would effectively inhibit tumor cells from reforming tumor mass, and would be less susceptible to therapeutic escape leading to recurrence.
These mechanisms include suppressing tumor growth and invasion by its influence on intracellular growth signals of different tumor subpopulations, eg, epidermal growth factor receptor (EGFR)/AKT in glioma cells in proliferation state, and NOTCH1/AKT in glioma cells in stem-like state.
ZR30 is an in vitro synthesized protein version of h-fibulin-3-v without signal peptide that has shown therapeutic efficacy in a human GBM intracranial (i.c.) xenograft model with a survival endpoint following even a single intratumoral administration. 5 The same multifaceted tumor suppression mechanisms of ZR30 were found in treated GBM cell lines and primary cultures, as also shown by induction of h-fibulin-3-v expression in GBM cells. 4, 5 Initially, EFEMP1 was reported to have a role in antiangiogenesis. 6 The cell context-dependent dual function of EFEMP1 in cancer appears to complicate its role in tumor vascularization. A provascularization function of EFEMP1 was implicated in ovarian cancer with lymph node metastasis, 7 and proven in a highly metastatic cell line of human pancreatic adenocarcinoma, 8 whereas antitumor vascularization function was also proven in a highly proliferative cell line of GBM. 9 Both were shown in s.c. xenograft models by overexpression of ectopic EFEMP1. Here we sought the effect of ZR30 on tumor vascularization using a clinically relevant intracranial GBM xenograft model, with a focus on angiogenesis and the vascularization potential of GBM cells.
Tumor cells express a vascular phenotype through a process called endothelial transdifferentiation (ETD). It is characterized by upregulation of genes in embryonic development that program hematopoietic and vascular development. 10 Tumor vascularization includes both angiogenesis and pathologic vascularization. The latter refers to leaky blood vessels formed by tumor cells, known as vasculogenic mimicry (VM) that supports rapidly growing tumors.
Although most of the blood vessels in tumor are derived from angiogenesis, VM is an important part of tumor vascularization associated with cancer progression, including GBM. [11] [12] [13] [14] [15] [16] [17] None of the antiangiogenic therapies currently in clinical use, which mainly target vascular endothelial growth factor (VEGF) and its receptor KDR, has shown a significant improvement in overall survival of GBM patients. 18 Agents inhibiting VM might not only improve antiangiogenic therapies through synergistic and/or additive effects, when coupled with current antiangiogenic therapies, but could significantly improve survival as well.
| MATERIAL S AND ME THODS

| Ethics statement
The use of fresh GBM tissue to establish primary cultures in this study was approved by the institutional review board of the University of 
| Human GBM primary cultures
Human GBM-derived syngeneic primary cultures used in this study were established in the Brain Tumor Research Laboratory, UC Irvine, following methods detailed previously. 19 In brief, single cells of GBM specimens were equally divided into 2 or 3 portions to culture in 2 (namely SA and NS) or 3 (namely SA, NS, and EC) conditions. In the SA condition, cells were cultured with DMEM/F12 medium supplemented with 10% FBS in collagen-coated (initial culture) or regular culture dishes (subsequent passages). In the NS condition, cells were cultured conclusion, multifaceted tumor suppression effects of human fibulin-3 variant include both suppression of angiogenesis and vasculogenic mimicry in GBM.
K E Y W O R D S
extracellular compartment, malignant glioma, novel cancer therapeutic, syngeneic primary culture, vasculogenic mimicry with DMEM/F12 medium supplemented with epidermal growth factor (EGF, 20 ng/mL), basic fibroblast growth factor (bFGF, 10 ng/mL), and 5% B27 (Invitrogen), initially in low-binding or 1% agar-coated dishes (for 3-4 weeks), then in adherent conditions in fibronectin (1 μg/cm 2 )coated dishes, and back and forth for at least 2 rounds of adherent and spheroid cultures. In the EC condition, adherent cultures were maintained in endothelial cell growth medium (PromoCell, http:// www.promo cell.com/) in fibronectin (1 μg/cm 2 )-coated dishes. The NS-conditioned cells were cultured in fibronectin-coated dishes prior to in vitro and in vivo analyses. All cells were cultured in a 37°C humid chamber containing 5% CO 2 .
Cells used in this study were validated to be free of mycoplasma by analyzing culture medium with MycoAlert PLUS Mycoplasma from Lonza and/or PCR-based Venor GeM Mycoplasma Detection Kit (Sigma-Aldrich). Identification of mutations in TP53, PTEN, IDH1, and IDH2 and DNA copy number variation of PTEN and EGFR were carried out using cDNA and DNA samples of GBM primary cultures, following PCR-based mutation assay with sequencing and comparative quantitative PCR, respectively, as described previously. 3, 19 The genetic identity profiles of 16 short tandem repeats were determined based on DNA samples by IDEXX RADIL, with results shown in Table 1 .
| Human fibulin-3 variant protein
ZR30 used in this study was provided by Ziren Research. It was made by an in vitro cell-free system based on the sequence of the h-fibulin-3-v, excluding the signal peptide, as detailed previously. 5
| Intracranial human GBM xenografts and immunohistochemistry
Each BALB/c nude mouse (SPF level, 5-6 weeks old, female; Shanghai SLAC Laboratory Animal Co.) was implanted with a guide cannula in the right frontal lobe, and then 3 μL glioma cells (9:1 mixture of 51A-GFP and 51B-RFP, a total of 1 × 10 5 cells) was injected through the guide cannula, as described previously. 5 Nineteen days after cell implantation, 5 μL PBS or ZR30 (180 ng/μL) was injected through the guide cannula into the cell implantation site. Two weeks after treatment, right hemispheres were removed from both groups of mice and processed for immunohistochemistry using primary Ab of anti-CD31 (ab182981; Abcam), as detailed previously. 17 Blood vessel density in xenografts was determined by positive signals counted by ImageJ based on images of a 20× lens, 5 images per section, 2 sections per mouse brain (frontal and hind parts), and 2-3 brains per group. (8, 9) ,vWA (15, 17) Note: amp, amplification; EC, adherent cultures maintained in endothelial cell growth medium in fibronectin (1 μg/cm2)-coated dishes; F, female; M, male; NS, cells cultured with DMEM/F12 medium supplemented with epidermal growth factor (20 ng/mL), basic fibroblast growth factor (10 ng/ mL), and 5% B27 (Invitrogen), initially in low-binding or 1% agar-coated dishes (for 3-4 weeks), then in adherent conditions in fibronectin (1 μg/cm2)coated dishes, and back and forth for at least 2 rounds of adherent and spheroid cultures; SA, cells cultured with DMEM/F12 medium supplemented with 10% FBS in collagen-coated (initial culture) or regular culture dishes (subsequent passages); trunc, truncated.
| Matrigel plug in vivo angiogenesis assay
| Matrigel-based tubular network assay
Corning Matrigel matrix (~10 mg/mL) was melted at 4°C overnight, added to ice-cold 24-well plates (0.2 mL/well) or 96-well plates (0.05-0.08 mL/well) and solidified by incubating at 37°C for more than 1 hour. The GBM cells were suspended in human endothelial basal medium (H1168B; Cell Biologics) supplemented with 2% FBS or DMEM/F12 with the addition of 10% FBS, then added in duplicates or triplicates to Matrigel-coated 24-or 96-well plates, in concentrations of 1-2 × 10 5 /well or 5 × 10 4 /well, respectively. Images were taken periodically (every 1 or 2 hours) under an inverted microscope for up to 24 hours, and analyzed using the Fiji distribution of ImageJ 20 at version ImageJ 2.0.0-rc-15/1.49k; Java 1.6.0_65 (available as a Life-Line version from https ://imagej.net/Downl oads). Table 2 .
| Real-time PCR quantification of gene expressions
| Statistical analysis
One-way ANOVA with post-hoc pairwise comparisons was used to determine ZR30's effect on VEGF-stimulated angiogenesis in 
| RE SULTS
| ZR30 suppresses tumor vascularization in human GBM i.c. xenografts
As shown previously, 19 i.c. implantation of a mixture of 100 000 cells of 51A and 51B (9:1) formed i.c. xenografts with the tumor mass largely composed of 51B cells that expressed highly proangiogenic genes or proteins, whereas the peritumoral zone was largely composed of 51A cells that expressed highly proinvasive genes or proteins. We used 
| ZR30 suppresses angiogenesis in Matrigel plugs in vivo
To examine the effect of ZR30 on angiogenesis, we undertook an in vivo Matrigel plug assay. As shown in Figure 2A Figure 2D confirmed our speculation that bFGF is required to maintain the viability of vessels following angiogenesis. Overall data from Matrigel angiogenesis assays using different angiogenesis-inducing agents consistently indicated the antiangiogenesis function of ZR30.
| ZR30 suppresses Matrigel matrix induction of ETD gene expression
Repeated Matrigel-based tubular network assay was carried out using primary cultures (51B, 97B, and 98B) that showed formation and epithelial-mesenchymal transition (EMT). The expression level of genes was shown as an absolute ratio to ACTB times 10 000, as shown in Table 3 . The 3 housekeeping genes and the gene involved in EMT (VIM) were highly expressed. Embryonic, pluripotency, and some hematopoietic vascular genes (NANOG, POU5F1, POU3F2, SALL2, and NOTCH4) were moderately expressed (more than 1 of 1000 copies of ACTB), and some other hematopoietic vascular genes (CDH5, PECAM1, GATA2, LMO2, and DLL4) had low expression (less than 1 of 1000 copies of ACTB). Other examined developmental and hematopoietic vascular genes (SOX2, OLIG2, VWF, and TEK) were not, or were rarely expressed (less than 1 of 10 000 copies of ACTB). Table 3 , comparison of these gene expression levels between Matrigel-3D and SA-2D conditions showed little change in Figure 4) . It was noted that NANOG and POU3F2 had lower basal expression levels in 51B, 26% and 6% compared with 98B, respectively.
As shown in
There are high basal levels of ETD genes in 97B, where SALL2 and CDH5 levels were approximately 20-fold higher compared with that in 51B and 98B, and POU3F2 levels were more than 40-fold higher compared with that in 51B. Although 97B cells formed mesh structures in Matrigel matrix and ZR30 significantly reduced the number of mesh structures by one third (P < .05), no effect of ZR30 was observed on the regulation of ETD genes in 97B, except for a 25% downregulation of CDH5, after 6 h of culture on Matrigel matrix.
We further examined mesh formation in Matrigel matrix by 51A, 97A, and 98A, the syngeneic primary cultures of 51B, 97B, and 98B, respectively (see Table 1 ), which were established under NS condi- with/without addition of ZR30, these ETD gene expression levels
were not significantly altered.
| ZR30 downregulates ETD genes highly expressed in GBM primary cultures
The above data shows ZR30's inhibition of Matrigel matrix-induced ETD gene expression in 51B and 98B cells, especially in cells with low basal expression levels. We then examined the effect of ZR30 on ETD genes in cells with high basal expression levels after a relatively long-term treatment in conditions that established the cultures. As shown in Figure 5 , 4 ETD genes (NANOG, POU5F1, NOTCH4, and CDH5) were significantly downregulated in 97B cells following 25 h of treatment by ZR30 in a dose-dependent manner.
Hematopoietic gene DDL4 was barely expressed in all SAconditioned GBM cells (see Table 1 ). In contrast, it was moderately expressed (10 000 × [absolute ratio to ACTB] = 22 ± 9.6) in 98E, a syngeneic culture of 98B and 98A established in EC conditions, at a level comparable with embryonic, pluripotency, and hematopoietic developmental genes in GBM primary cultures (see Table 3 ). Other hematopoietic vascular genes (NOTCH4, PECAM1, and CDH5) were also expressed at a higher level in 98E, compared to 98B. As shown in Figure 5 The GBM subpopulation of cells in 98E harbors a new mutation in the PTEN gene (see Table 1 ), indicating a later evolved subpopulation with vascular features. Results of this study suggest that tumor cells in a vascular state, as well as those in the proliferation state with plasticity to switch into a vascular state, could have arisen at the advanced stages of cancer evolution, through some of the known selection pressure forces, including an ever-changing tumor microenvironment, overgrowth, hypoxia, and low pH.
| ZR30 does not affect GBM cell growth in vitro
The involvement of hypoxia-related genes in VM 10 is consistent with the finding that VM-forming tumor cells reside within the tumor mass core.
Our current approach in exploring the role of ZR30 on inhibition of vascularization in GBM could not address whether ZR30 could destabilize the existing blood vessels in GBM. The animal experiments with nude mice forming i.c. xenografts showed rapid body weight reduction 1 week after treatment; on average, the reduction was 10% in both PBS and ZR30 treatment groups. This confirms that the treatment was given at the time of the tumors' aggressive growth. The marked reduction of BVD (70% reduction compared with control) by ZR30 in GBM i.c. xenografts at the stage of aggressive growth supports ZR30's effect in suppressing new blood vessel formation and possibly destabilizing newly formed blood vessels. This is an intriguing question for a future study.
Both PI3K/AKT signaling and MMP2 have been shown to be related regulators in the formation of vascular-like networks. 23, 24 We have shown ZR30's effect on inhibition of extracellular activation of MMP2 and attenuation of phosphorylation of AKT in both types of glioma cells with high expression of NOTCH1 or EGFR. 5 Along with suppression of GBM cell ETD, these findings suggest at least 3 convergent, but independent, mechanisms of action of ZR30 in suppression of GBM vascularization.
In the last 2 decades, attempts at "starving cancer to death" by targeting tumor blood vessels have failed to improve overall survival. 25 The reasons include: (i) failure to see cancer's capability to change from a high proliferation to high invasion state; and (ii) targeting VEGF and F I G U R E 6 Effect of ZR30 on glioma cell growth. A, CCK-8 colorimetric assay for the determination of cell growth, measured daily (for 97B) or every 3 days (for 97A and 98A) for absorbance at 450 nm by cells (1000 cells/well in 96-well plate with 5 replicates in 0.1 mL culture medium with or without ZR30), which were changed after CCK-8 assay. B, Cell doubling time calculated based on the number of viable cell with exclusion of Trypan blue (0.02%), counted 1 week after seeding 20 000 cells/well in a 12-well plate with 3 replicates in 1 mL culture medium with or without ZR30. The assay was repeated on cells with or without 2 weekly passages its receptor KDR works on suppressing angiogenesis by normal endothelial cells, but not tumor cells, which have undergone ETD to form VM or vessel cooption, where tumor cells migrate along the preexisting vessels of the host organ. 26 ZR30's dual function in suppression of angiogenesis and VM is unique in targeting tumor vascularization.
Hence, ZR30 as a novel cancer therapeutic, directly deliverable into the tumor site and functioning in the extracellular compartment, could effectively treat GBM through its multifaceted and unique mechanisms of action, including suppression of tumor cell growth and invasive features and its supporting vascular microenvironment.
